共 33 条
- [21] Durable Remissions after Discontinuation of Combined Targeted Treatment in Patients with Chronic Lymphocytic Leukemia (CLL) Harbouring a High-Risk Genetic Lesion (del(17p)/TP53 Mutation)BLOOD, 2018, 132Cramer, Paulavon Tresckow, JuliaBahlo, JasminRobrecht, SandraTausch, EugenFuerstenau, MoritzLangerbeins, PetraAl-Sawaf, OthmanFink, Anna-MariaFischer, KirstenWendtner, Clemens-MartinEichhorst, BarbaraKneba, MichaelStilgenbauer, StephanHallek, Michael
- [22] Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines AgencyBlood Cancer Journal, 13Gian Matteo RigolinPier Paolo OlimpieriValentina SummaSimone CelantLydia ScarfòLucia TognoloMaria Pia BallardiniAntonio UrsoMariarosaria SessaSilvia GambaraFrancesca CuraMonica FortiniPaolo GhiaAntonio CuneoPierluigi Russo
- [23] Cost-Utility of Venetoclax Plus Obinutuzumab for Treatment-Naive Patients with Chronic Lymphocytic Leukemia without Del17p/TP53-Mutation Compared to Chlorambucil Plus ObinutuzumabBLOOD, 2022, 140 : 2163 - 2164Slot, MatildeNiemann, Carsten UtoftRisor, Bettina WulffEhlers, Lars HolgerRotbain, Emelie
- [24] Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab ( iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up AnalysesBLOOD, 2023, 142Jain, NitinThompson, PhilipJain, AkhilBurger, Jan A.Ferrajoli, AlessandraSenapati, JayastuTakahashi, KoichiSwaminathan, MaheshEstrov, ZeevBorthakur, GautamBose, PrithvirajKadia, Tapan M.Pemmaraju, NaveenSasaki, KojiBansal, DivyamKonopleva, Marina Y.Jabbour, EliasGarg, NaveenWang, XuemeiKanagal-Shamanna, RashmiPatel, Keyur P.Wang, WeiWang, Sa A.Jorgensen, Jeffrey L.Lopez, WandaAyala, AnaPlunkett, WilliamGandhi, VarshaKantarjian, Hagop M.O'Brien, Susan M.Keating, Michael J.Wierda, William G.
- [26] Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic LeukemiaBLOOD, 2016, 128 (22)Barr, PaulRobak, TadeuszOwen, Carolyn J.Tedeschi, AlessandraBairey, OsnatBartlett, Nancy L.Burger, JanHillmen, PeterCoutre, StevenDevereux, StephenGrosicki, SebastianMcCarthy, HelenLi, JianyongSimpson, DavidOffner, FritzMoreno, CarolZhou, CathyStyles, LoriJames, Danelle F.Kipps, Thomas J.Ghia, Paolo
- [27] First-Line Ibrutinib Plus Venetoclax in MCL for Older Patients or Those with a TP53 Mutation: Ongoing Open-Label Arm of the PCYC-1143 Phase 3 SYMPATICO StudyCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S259 - S259Wang, Michael L.Jurczak, WojciechEckert, KarlLin, JenniferNeuenburg, JuttaTam, Constantine
- [28] Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL CampusBLOOD, 2020, 136Visentin, AndreaMauro, Francesca RomanaPietrasanta, DanielaFresa, AlbertoVitale, CandidaCiolli, StefaniaCassin, RamonaCibien, FrancescaSportoletti, PaoloGentile, MassimoRigolin, Gian MatteoQuaglia, Francesca M.Murru, RobertaGozzetti, AlessandroMolica, StefanoMarchetti, MoniaScarfo, LydiaReda, GianluigiCoscia, MartaLaurenti, LucaPizzolo, GiovanniSemenzato, GianpietroFoa, RobinCuneo, AntonioTrentin, Livio
- [29] 17P (TP53) Deletion Determines Worse Survival in Diffuse Large B-Cell Lymphoma Patients After First-Line Treatment With Immunochemotherapy: A Retrospective Study of 151 PatientsCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S435 - S436Alonso, DavidNavarro, AlmudenaAlejo, ElenaGarcia, MariaAntonio Queizan, JoseCabero, AlmudenaEugenia Alonso, MariaGarcia-Bacelar, AnaDavila, JulioLabrador, JorgeFernandez, SilviaAlbarran, BeatrizAguilar, CarlosPardal, EmiliaDe Cabo, ErickJesus Penarrubia, MariaCidoncha, BorjaMartinez, GerardoVillaescusa, TeresaMaria Navarro, JosePatricia Gomez, SandraPuerta, CarlosGarcia-Jaen, PabloGabriela Zapata, EvelynClavo, DiegoJose Malaver, RafaelTeresa Fuentes, CristinaFernandez, AdolfoSantos, CarmenMartin, AlejandroAlcoceba, MiguelNorma Gutierrez, Carmen
- [30] Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective StudyBLOOD, 2016, 128 (22)Mauro, Francesca RomanaTedeschi, AlessandraPiciocchi, AlfonsoMotta, MarinaIannella, EmiliaFarina, LuciaScarfo, LydiaMarasca, RobertoCoscia, MartaCortelezzi, AgostinoLaurenti, LucaMelpignano, AngelaZinzani, Pier LuigiMolica, StefanoRe, FrancescaAndriani, AlessandroVincelli, Donatella IolandaVisco, CarloGozzetti, AlessandroOrlandi, Ester MariaTrentin, LivioTani, MonicaCalifano, CatelloTagariello, GiuseppeGhia, PaoloCaputo, Maria DeniseSalaroli, AdrianoInnocenti, IdannaFrustaci, AnnaVitale, CandidaPetulla, Martade Fabritiis, PaoloVignetti, MarcoFazi, PaolaFoa, Robin